Numerous animal studies have revealed that CD40/CD40L inhibitors can successfully reduce proteinuria and lengthen survival in mice with LN, as well as delay and reduce illness flares in mice prone to LN. This evidence concerns the gene CD40LG and lobular neoplasia.